210 related articles for article (PubMed ID: 36692895)
21. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
[TBL] [Abstract][Full Text] [Related]
22. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
Salavisa M; Serrazina F; Ladeira AF; Correia AS
Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
25. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.
Lehnert T; Röver C; Köpke S; Rio J; Chard D; Fittipaldo AV; Friede T; Heesen C; Rahn AC
Syst Rev; 2022 Jul; 11(1):134. PubMed ID: 35778721
[TBL] [Abstract][Full Text] [Related]
28. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
[TBL] [Abstract][Full Text] [Related]
29. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
30. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
31. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
32. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
33. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
[TBL] [Abstract][Full Text] [Related]
35. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
38. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
39. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Daruwalla C; Shaygannejad V; Ozakbas S; Havrdova EK; Horakova D; Alroughani R; Boz C; Patti F; Onofrj M; Lugaresi A; Eichau S; Girard M; Prat A; Duquette P; Yamout B; Khoury SJ; Sajedi SA; Turkoglu R; Altintas A; Skibina O; Buzzard K; Grammond P; Karabudak R; van der Walt A; Butzkueven H; Maimone D; Lechner-Scott J; Soysal A; John N; Prevost J; Spitaleri D; Ramo-Tello C; Gerlach O; Iuliano G; Foschi M; Ampapa R; van Pesch V; Barnett M; Shalaby N; D'hooghe M; Kuhle J; Sa MJ; Fabis-Pedrini M; Kermode A; Mrabet S; Gouider R; Hodgkinson S; Laureys G; Van Hijfte L; Macdonell R; Oreja-Guevara C; Cristiano E; McCombe P; Sanchez-Menoyo JL; Singhal B; Blanco Y; Hughes S; Garber J; Solaro C; McGuigan C; Taylor B; de Gans K; Habek M; Al-Asmi A; Mihaela S; Castillo Triviño T; Al-Harbi T; Rojas JI; Gray O; Khurana D; Van Wijmeersch B; Grigoriadis N; Inshasi J; Oh J; Aguera-Morales E; Fragoso Y; Moore F; Shaw C; Baghbanian SM; Shuey N; Willekens B; Hardy TA; Decoo D; Sempere AP; Field D; Wynford-Thomas R; Cunniffe NG; Roos I; Malpas CB; Coles AJ; Kalincik T; Brown JWL
Mult Scler; 2023 Jun; 29(7):875-883. PubMed ID: 36851894
[TBL] [Abstract][Full Text] [Related]
40. Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J; Roos I; Kalincik T; Lorscheider J; Galli E; Benkert P; Schädelin S; Sharmin S; Einsiedler M; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Ziemssen T; Siepmann T; Yaldizli Ö
Brain Behav; 2024 May; 14(5):e3498. PubMed ID: 38688877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
